FDA panel backs Amgen's T-Vec, with caveats
This article was originally published in Scrip
Executive Summary
An FDA panel on 29 April endorsed Amgen's oncolytic immunotherapy T-Vec (talimogene laherparepvec), although that support from the agency's outside advisers came with several caveats.